BIOGEN ($BIIB) is expected to release its quarterly earnings data on Thursday, May 1st before market open, per Finnhub. Analysts are expecting revenue of $2,290,274,431 and earnings of $3.53 per share.
You can see Quiver Quantitative's $BIIB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOGEN Insider Trading Activity
BIOGEN insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- STEPHEN A SHERWIN sold 8,760 shares for an estimated $1,314,141
- PRIYA SINGHAL (Head of Development) sold 110 shares for an estimated $17,293
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIOGEN Hedge Fund Activity
We have seen 402 institutional investors add shares of BIOGEN stock to their portfolio, and 457 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 3,006,155 shares (-58.9%) from their portfolio in Q4 2024, for an estimated $459,701,222
- PACER ADVISORS, INC. added 2,648,024 shares (+13574.7%) to their portfolio in Q4 2024, for an estimated $404,935,830
- RA CAPITAL MANAGEMENT, L.P. removed 1,184,456 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $181,127,011
- D. E. SHAW & CO., INC. added 1,174,960 shares (+270.1%) to their portfolio in Q4 2024, for an estimated $179,674,883
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,156,500 shares (-27.2%) from their portfolio in Q4 2024, for an estimated $176,851,980
- AMERIPRISE FINANCIAL INC removed 1,006,463 shares (-87.5%) from their portfolio in Q4 2024, for an estimated $153,908,321
- VAN ECK ASSOCIATES CORP added 967,523 shares (+977.9%) to their portfolio in Q4 2024, for an estimated $147,953,617
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOGEN Government Contracts
We have seen $152,168 of award payments to $BIIB over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- QALSODY BULK: $43,476
- QALSODY 6.7MG/ML INJ,SOLN: $32,607
- QALSODY (TOFERSEN) - EMERGENCY PHARMACY: $21,738
- QALSODY (TOFERSEN) 6.7MG SOLN (2 VIALS) NDC: 64406-0109-01: $21,738
- EMERGENCY PHARMACEUTICAL - QUALSODY (TOFERSEN): $21,738
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BIOGEN Congressional Stock Trading
Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 02/25.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BIOGEN Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 02/13/2025
To track analyst ratings and price targets for BIOGEN, check out Quiver Quantitative's $BIIB forecast page.
BIOGEN Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 7 analysts offer price targets for $BIIB in the last 6 months, with a median target of $180.0.
Here are some recent targets:
- An analyst from HSBC set a target price of $118.0 on 04/28/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $265.0 on 02/13/2025
- Ami Fadia from Needham set a target price of $270.0 on 02/12/2025
- Mohit Bansal from Wells Fargo set a target price of $165.0 on 02/12/2025
- Geoff Meacham from Citigroup set a target price of $160.0 on 02/12/2025
- Michael Yee from Jefferies set a target price of $180.0 on 12/09/2024
- Brian Skorney from Robert W. Baird set a target price of $300.0 on 11/15/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
